Final results of a phase II study of pembrolizumab as first-line treatment in advanced cutaneous squamous cell carcinomas (CSCCs)

被引：0
|
作者：
Maubec, E. [1 ]
Boubaya, M. [2 ]
Deschamps, L. [3 ]
Beylot-Barry, M. [4 ]
Petrow, P. [5 ]
Scheer-Senyarich, I. [1 ]
Basset-Seguin, N. [6 ]
Marqueste, C. Gaudy [7 ]
Quereux, G. [8 ]
Bloch-Queyrat, C. [9 ]
Leccia, M-T. [10 ]
Stefan, A. [11 ]
Saiag, P. [12 ]
Grange, F. [13 ]
Meyer, N. [14 ]
Rat, S. Dalac [15 ]
Alloux, C. [16 ]
Lopez, I. [17 ]
Tibi, A. [16 ]
Levy, V. [18 ]
机构：
[1] Hop Avicenne, AP HP, Dermatol Dept, Bobigny, France
[2] Hop Avicenne, AP HP, Unite Rech Clin, Bobigny, France
[3] Hop Bichat Claude Bernard, APHP, Pathol, Paris, France
[4] CHU Bordeaux, Dermatol Dept, Hop St Andre, Bordeaux, France
[5] Polyclin St Come, Radiol, Compiegne, France
[6] Hop St Louis, AP HP, Paris, France
[7] CHU La Timone Enfants, AP HM, Dermatol Dept, Marseille, France
[8] CHU Nantes Hotel Dieu, Dermatol, Nantes, France
[9] Hop Avicenne, AP HP, Res Clin Unit, Bobigny, France
[10] CHU Grenoble Alpes, Dermatol, Site Nord La Tronche, La Tronche, France
[11] CHU Caen, Dermatol, Hop Cote Nacre, Caen, France
[12] Hop Ambroise Pare, AP HP, Dermatol & Oncol Dept, Boulogne, France
[13] Ctr Hosp Valence, Dermatol, Valence, France
[14] Ctr Hosp Univ Toulouse, Dermatol, Hop Larrey, Toulouse, France
[15] CHU Dijon, Dermatol, Dijon, France
[16] APHP, Pharm, Agence Gen Equipements & Prod Sante, Paris, France
[17] Polyclin St Come Assoc Cabinet Radiol & Imagerie, Radiol, Compiegne, France
[18] Hop Avicenne, Clin Res, Bobigny, France
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2273
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1139P
引用
收藏
页码：S682 / S683
页数：2
相关论文
共 50 条
  • [21] Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
    Motzer, Robert J.
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Gruenwald, Viktor
    Hutson, Thomas E.
    Alekseev, Boris
    Rha, Sun Young
    Merchan, Jaime
    Goh, Jeffrey C.
    Lalani, Aly-Khan A.
    De Giorgi, Ugo
    Melichar, Bohuslav
    Hong, Sung-Hoo
    Gurney, Howard
    Mendez-Vidal, Maria Jose
    Kopyltsov, Evgeny
    Tjulandin, Sergei
    Gordoa, Teresa Alonso
    Kozlov, Vadim
    Alyasova, Anna
    Winquist, Eric
    Maroto, Pablo
    Kim, Miso
    Peer, Avivit
    Procopio, Giuseppe
    Takagi, Toshio
    Wong, Shirley
    Bedke, Jens
    Schmidinger, Manuela
    Rodriguez-Lopez, Karla
    Burgents, Joseph
    He, Cixin
    Okpara, Chinyere E.
    Mckenzie, Jodi
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (11) : 1222 - 1228
  • [22] Anti PD-1 Checkpoint Inhibitor As a First-Line Treatment for Advanced Cutaneous Squamous Cell Carcinoma
    Bopota, Katerina
    Donnelly, Oliver
    Borumandi, Farzad
    JOURNAL OF CRANIOFACIAL SURGERY, 2023, 34 (03) : E247 - E249
  • [23] Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study
    Ardavanis, A
    Tryfonopoulos, D
    Alexopoulos, A
    Kandylis, C
    Lainakis, G
    Rigatos, G
    BRITISH JOURNAL OF CANCER, 2005, 92 (04) : 645 - 650
  • [24] Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer
    Zeuli, M
    Nardoni, C
    Pino, MS
    Gamucci, T
    Gabriele, A
    Ferraresi, V
    Giannarelli, D
    Cognetti, F
    ANNALS OF ONCOLOGY, 2003, 14 (09) : 1378 - 1382
  • [25] Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer
    J Feliu
    J M Vicent
    C García-Girón
    M Constela
    E Fonseca
    J Aparicio
    M Lomas
    L Antón-Aparicio
    F J Dorta
    M González-Barón
    British Journal of Cancer, 2004, 91 : 1758 - 1762
  • [26] Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer
    Feliu, J
    Vicent, JM
    García-Girón, C
    Constela, M
    Fonseca, E
    Aparicio, J
    Lomas, M
    Antón-Aparicio, L
    Dorta, FJ
    González-Barón, M
    BRITISH JOURNAL OF CANCER, 2004, 91 (10) : 1758 - 1762
  • [27] Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study
    A Ardavanis
    D Tryfonopoulos
    A Alexopoulos
    C Kandylis
    G Lainakis
    G Rigatos
    British Journal of Cancer, 2005, 92 : 645 - 650
  • [28] Updated results of a phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)
    Galle, P. R.
    Kim, R. D.
    Sung, M. W.
    Harris, W. P.
    Waldschmidt, D.
    Cabrera, R.
    Mueller, U.
    Nakajima, K.
    Ishida, T.
    El-Khoueiry, A. B.
    ANNALS OF ONCOLOGY, 2020, 31 : S691 - S692
  • [29] Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial
    Feldman, Darren R.
    Ged, Yasser
    Lee, Chung-Han
    Knezevic, Andrea
    Molina, Ana M.
    Chen, Ying-Bei
    Chaim, Joshua
    Coskey, Devyn T.
    Murray, Samuel
    Tickoo, Satish K.
    Reuter, Victor E.
    Patil, Sujata
    Xiao, Han
    Aghalar, Jahan
    Apollo, Arlyn J.
    Carlo, Maria I.
    Motzer, Robert J.
    Voss, Martin H.
    CANCER, 2020, 126 (24) : 5247 - 5255
  • [30] Phase II trial of satraplatin (S) and paclitaxel (P) in first-line advanced non-small cell lung cancer (NSCLC) treatment: Final results
    Thompson, D. S.
    Spigel, D. R.
    Hainsworth, J. D.
    Jones, S. F.
    Burris, H. A., III
    Sade, L.
    Raefsky, E.
    Greco, F. A.
    Yun, S.
    Noursalehi, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345